<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03266172</url>
  </required_header>
  <id_info>
    <org_study_id>205017</org_study_id>
    <nct_id>NCT03266172</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses</brief_title>
  <official_title>A Three Part, Non-randomized, Open Label Study Designed to Assess the Pharmacokinetics of GSK2982772 Following Administration of Minitab Modified Release Formulations in a Capsule Relative to an Immediate Release Reference Tablet Formulation (Part A), the Pharmacokinetics of Escalating, Repeat Doses of a Selected Minitab Modified Release Prototype (Part B) , and the Pharmacokinetics of GSK2982772 Following Administration of Modified Release Tablet Formulations in the Fed and Fasted State (Part C) in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2982772 is a first-in-class, highly selective, receptor-interacting protein-1 (RIP1)&#xD;
      kinase inhibitor being developed for the treatment of inflammatory bowel disease, plaque&#xD;
      psoriasis (PsO), rheumatoid arthritis (RA) and other disease conditions. PK data from the&#xD;
      first time in human (FTIH) study for GSK2982772 showed that the half life of GSK2982772 was&#xD;
      short (approximately 2 to 3 hours). A once daily (QD) formulation would be more convenient&#xD;
      from a subject perspective and could offer the advantage of providing a flatter GSK2982772&#xD;
      concentration time profile. Following completion of Parts A and B, it was determined that the&#xD;
      slowest minitab formulation provided a PK profile suitable for QD dosing but this formulation&#xD;
      was susceptible to a food effect. This study will evaluate the pharmacokinetics of GSK2982772&#xD;
      following administration of different minitab MR formulations in a capsule relative to an IR&#xD;
      reference tablet formulation, the pharmacokinetics of selected MR formulation in capsule&#xD;
      following repeat doses for 3 days and to compare the pharmacokinetics of GSK2982772 following&#xD;
      administration of MR tablet formulations in the fed and fasted state relative to an IR tablet&#xD;
      formulation. The study is divided into three parts: Part A will be a non-randomized 6&#xD;
      periods, sequential, 6-way fixed sequence design in which up to 4 MR minitab formulations in&#xD;
      a capsule will be evaluated. Periods 1, 2, and 3 will evaluate a slow MR release duration&#xD;
      (nominally 24 hours), a fast MR release duration (nominally 10 hours), and IR tablet&#xD;
      respectively. Periods 4, 5 and 6 will have flexible dose regimen and it will depend on the&#xD;
      outcomes of Period 1 to 3. Subjects will be admitted to the clinic the previous day before&#xD;
      dosing. Each in-patient period will consist of 3 days and 2 nights followed by a minimum&#xD;
      washout period of 7 days between doses, for both Part A and C. In Part A and C, 16 healthy&#xD;
      subjects will be enrolled such that at least 12 evaluable subjects complete the study. Part B&#xD;
      will be an open-label, repeat dose study in which the selected MR minitab formulation in&#xD;
      capsule will be evaluated. Each in-patient period will consist of 5 days and 4 nights. There&#xD;
      will be a minimum of 7 days washout period between the last morning dose of one period and&#xD;
      the first dose of the next period. In Part B, 10 healthy subjects will be enrolled such that&#xD;
      at least 6 evaluable subjects complete the study. Part C of the study will be a&#xD;
      non-randomised 6 period, sequential, fixed sequence crossover design in which MR tablet&#xD;
      formulations will be evaluated. Periods 1 and 2 will evaluate single dose administration of a&#xD;
      240 milligram (mg) MR tablet and the 240 mg IR tablet (reference), respectively. Periods 3,&#xD;
      4, 5 and 6 will be flexible and the dosing regimen will be dependent on the outcome of&#xD;
      Periods 1 and 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Actual">November 21, 2018</completion_date>
  <primary_completion_date type="Actual">November 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A of the study will be a non-randomized 6 period, sequential, 6-way fixed sequence design. Part B of the study will be a repeat dose study. Part C of the study will be a non-randomized 6 period, sequential, fixed sequence crossover design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Participants in the 'Safety Population' for whom a Pharmacokinetic (PK) sample was obtained and analyzed were part of PK Population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) of GSK2982772 in MT Formulation :Part A</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) of GSK2982772 in MT Formulation: Part A</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24) of GSK2982772 in MT Formulation: Part A</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12) of GSK2982772 in MT Formulation: Part A</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of GSK2982772 in MT Formulation: Part A</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A</measure>
    <time_frame>12 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for C12hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for C24hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose (test)</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT (test) / Geometric mean of AUC (0-inf) of IR Formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frelformulation Based on AUC (0-24) of GSK2982772 in Part A</measure>
    <time_frame>Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose (test)</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MT (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frelformulation Based on Cmax of GSK2982772 in Part A</measure>
    <time_frame>Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose(test)</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel was calculated as Geometric mean of Cmax of MT Formulation (test)/ Geometric mean of Cmax of IR Formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A</measure>
    <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A</measure>
    <time_frame>Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A</measure>
    <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A</measure>
    <time_frame>Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Tmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of GSK2982772 in MT Formulation: Part A</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Tmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-t).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-t).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of GSK2982772 for IR Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of GSK2982772 for MM Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C12 of GSK2982772 in Part C: Fasted State</measure>
    <time_frame>12 hours post-dose</time_frame>
    <description>Blood samples was collected at indicated time point for analysis of C12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C24 of GSK2982772 in Part C: Fasted State</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Blood samples was collected at indicated time point for analysis of C24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose(test)</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MM formulation (test) / Geometric mean of AUC (0-t) of IR Formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose(test)</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MM Fasted formulation (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A</measure>
    <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after a high fat meal. Frel for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT Fed formulation (test) / Geometric mean of AUC (0-inf) of MT Fasted Formulation (reference) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A</measure>
    <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772 after a high fat meal. Frel for Cmax was calculated as Geometric mean of Cmax of MT Fed formulation (test) / Geometric mean of Cmax of MT Fasted Formulation (reference) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24) of GSK2982772 in Part B</measure>
    <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GSK2982772 in Part B</measure>
    <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GSK2982772 in Part B</measure>
    <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-24) of GSK2982772 After Meal in Part C</measure>
    <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GSK2982772 After Meal in Part C</measure>
    <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C12 of GSK2982772 After Meal in Part C</measure>
    <time_frame>12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of C12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) of GSK2982772 After Meal in Part C</measure>
    <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf) of GSK2982772 After Meal in Part C</measure>
    <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf) after meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-12) of GSK2982772 After Meal in Part C</measure>
    <time_frame>Pre-dose and at 2, 4, 6, 8, 10, and 12 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of AUC (0-12) after meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C</measure>
    <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after meal. Frel for Auc (0-t) was calculated as Geometric mean of AUC (0-t) of MM Fed formulation (fed) / Geometric mean of AUC (0-t) of MM Fasted Formulation (fasted) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frelformulation Based on Cmax of GSK2982772 After Meal in Part C</measure>
    <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 after meal. Frel for Cmax was calculated as Geometric mean of Cmax of MM Fed formulation (test) / Geometric mean of Cmax of MM Fasted Formulation (reference) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GSK2982772 After Meal in Part C</measure>
    <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Tmax of GSK2982772 after meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. All participants who receive at least 1 dose of study treatment and were included in Safety Population. Participants will be analyzed according to the treatment they actually received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AE and SAE in Part B</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AE and SAE in Part C</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Blood samples were collected to analyze hematology parameters like platelet count, white blood cell (WBC) count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Abnormal Urinalysis Dipstick Results: Part A</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Abnormal Urinalysis Dipstick Results: Part B</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Abnormal Urinalysis Dipstick Results: Part C</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and Corrected QT (QTc) intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Abnormal ECG Findings: Part B</measure>
    <time_frame>Up to Day 22</time_frame>
    <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Abnormal ECG Findings: Part C</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure: Part A</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
    <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate: Part A</measure>
    <time_frame>Baseline (Day 1 Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
    <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Respiration Rate: Part A</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
    <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Temperature: Part A</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
    <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure: Part B</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours</time_frame>
    <description>SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate: Part B</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours</time_frame>
    <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Respiration Rate: Part B</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4 24 hours</time_frame>
    <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Temperature: Part B</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours</time_frame>
    <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure: Part C</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
    <description>SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate: Part C</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
    <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Respiration Rate: Part C</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
    <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Temperature: Part C</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
    <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Subjects in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Part B will receive GSK2982772 MR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects in Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Part C will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2982772 Modified Release</intervention_name>
    <description>GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.</description>
    <arm_group_label>Subjects in Part A</arm_group_label>
    <arm_group_label>Subjects in Part B</arm_group_label>
    <arm_group_label>Subjects in Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2982772 Immediate Release</intervention_name>
    <description>In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.</description>
    <arm_group_label>Subjects in Part A</arm_group_label>
    <arm_group_label>Subjects in Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be 18 to 65 years of age inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Subjects who are overtly healthy as determined by medical evaluation including medical&#xD;
             history, physical examination, laboratory tests, and cardiac monitoring.&#xD;
&#xD;
          -  Body weight greater than and equal to 50 kilogram (kg) and body mass index within the&#xD;
             range 19.0 to 32.0 kilogram per meter square (kg/m^2) (inclusive).&#xD;
&#xD;
          -  A male subject must agree to use a highly effective contraception during the treatment&#xD;
             period and for at least 90 days after the last dose of study treatment and refrain&#xD;
             from donating sperm during this period.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is not pregnant, not breastfeeding,&#xD;
             not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the&#xD;
             contraceptive during the treatment period and for at least 30 days before and 30 days&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal&#xD;
             (GI), endocrine, hematological, or neurological disorders capable of significantly&#xD;
             altering the absorption, metabolism, or elimination of drugs; constituting a risk when&#xD;
             taking the study treatment; or interfering with the interpretation of data.&#xD;
&#xD;
          -  Parts A and C only: Any history of suicidal behavior within the past 6 months or any&#xD;
             history of attempted suicide in a subject's lifetime.&#xD;
&#xD;
          -  Part B only: Subjects with current history of suicidal ideation behavior as measured&#xD;
             using the columbia-suicide severity rating scale (C-SSRS) or a history of attempted&#xD;
             suicide.&#xD;
&#xD;
          -  History of clinically significant psychiatric disorders as judged by the investigator.&#xD;
             Depression requiring treatment in the last 2 years.&#xD;
&#xD;
          -  History of herpes zoster (shingles) reactivation.&#xD;
&#xD;
          -  History or diagnosis of obstructive sleep apnea.&#xD;
&#xD;
          -  History of a significant respiratory disorder. Childhood asthma that has fully&#xD;
             resolved is permitted.&#xD;
&#xD;
          -  History or current evidence of febrile seizures, epilepsy, convulsions, significant&#xD;
             head injury, or other significant neurologic conditions.&#xD;
&#xD;
          -  A positive diagnostic tuberculosis (TB) test at screening defined as a positive&#xD;
             QuantiFERON-TB Gold test or T-spot test. In cases where the QuantiFERON or T spot test&#xD;
             is indeterminate, the subject may have the test repeated once, but they will not be&#xD;
             eligible for the study unless the second test is negative.&#xD;
&#xD;
          -  History of GI surgery (with exception of appendectomy).&#xD;
&#xD;
          -  History of cholecystectomy or gall stones.&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hay fever is allowed unless it is active.&#xD;
&#xD;
          -  ALT greater than 1.5 times upper limit of normal (ULN).&#xD;
&#xD;
          -  Bilirubin greater than 1.5 times ULN (isolated bilirubin greater than 1.5 times ULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin less than 35 percentage&#xD;
             of total).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome).&#xD;
&#xD;
          -  Corrected QT interval (QTc) greater than 450 millisecond (msec).&#xD;
&#xD;
          -  Past or intended use of over-the-counter or prescription medication including herbal&#xD;
             medications within 7 days prior to dosing (paracetamol/acetaminophen [up to 2 gram (g)&#xD;
             per day], hormone replacement therapy and hormonal contraception are permitted).&#xD;
&#xD;
          -  Live or attenuated vaccine(s) within 30 days of enrolment, or plans to receive such&#xD;
             vaccines during the study or plans to receive a vaccine within 30 days + 5 half-lives&#xD;
             of the last dose of study medication.&#xD;
&#xD;
          -  Subject in the study would result in loss of blood or blood products in excess of 500&#xD;
             milliliter (mL) within a 56 day period; therefore donation or loss of greater than 400&#xD;
             mL of blood within the previous 3 months.&#xD;
&#xD;
          -  Exposure to more than 4 new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Current enrolment or past participation within the last 3 months before signing of&#xD;
             consent in this or any other clinical study involving an investigational study&#xD;
             treatment or any other type of medical research.&#xD;
&#xD;
          -  Subjects who have previously been enrolled in this study. Subjects in Part A of this&#xD;
             study are not permitted to participate in Part B. Subjects in Parts A or B of this&#xD;
             study are not permitted to participate in Part C.&#xD;
&#xD;
          -  Current or history of renal disease or estimated glomerular filtration rate (GFR) by&#xD;
             Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation calculation less&#xD;
             than 60 mL/minutes(min)/1.73m^2 at screening.&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) at screening Positive Hepatitis C&#xD;
             antibody test result at screening or within 3 months prior to first dose. As potential&#xD;
             for and magnitude of immunosuppression with this compound is unknown, subjects with&#xD;
             presence of hepatitis B core antibody (HBcAb) should be excluded. Subjects positive&#xD;
             for HBsAg and/or positive for anti-HBc antibody (regardless of anti-HBs antibody&#xD;
             status) are excluded.&#xD;
&#xD;
          -  An elevated C-reactive protein (CRP) outside the normal reference range.&#xD;
&#xD;
          -  Part B only: A positive anti-nuclear antibody (ANA) outside the normal reference&#xD;
             range.&#xD;
&#xD;
          -  Confirmed positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) antibody test.&#xD;
&#xD;
          -  Regular use of known drugs of abuse, or history of drug or alcohol abuse in the past 5&#xD;
             years.&#xD;
&#xD;
          -  Regular alcohol consumption within 6 months prior to the study defined as an average&#xD;
             weekly intake of greater than 21 units for males or greater than 14 units for females.&#xD;
             One unit is equivalent to 8 g of alcohol: a half-pint (approximately 240 mL) of beer,&#xD;
             1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.&#xD;
&#xD;
          -  Current use or history of regular use of tobacco- or nicotine-containing products&#xD;
             within 6 months prior to screening. A carbon monoxide breath test reading of greater&#xD;
             than 10 parts per million (ppm).&#xD;
&#xD;
          -  Sensitivity to any of the study treatments, or components thereof, or drug or other&#xD;
             allergy that, in the opinion of the investigator or medical monitor, contraindicates&#xD;
             participation in the study.&#xD;
&#xD;
          -  Unwilling or unable to swallow multiple size 0-00 capsules as part of study&#xD;
             participation.&#xD;
&#xD;
          -  Subjects who do not have suitable veins for multiple venipunctures/cannulation as&#xD;
             assessed by the investigator at screening.&#xD;
&#xD;
          -  Total cholesterol greater than or equal to 300 milligram/deciliter (mg/dL) (greater&#xD;
             than or equal to 7.77 millimoles per liter [mmol]/L]) or triglycerides greater than or&#xD;
             equal to 250 mg/dL (greater than or equal to 2.82 mmol/L).&#xD;
&#xD;
          -  Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Tompson DJ, Whitaker M, Pan R, Johnson G, Fuller T, McKenzie L, Zann V, Powell M, Abbott-Banner K, Hawkins S. Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772. Pharm Res. 2021 Jul;38(7):1235-1245. doi: 10.1007/s11095-021-03059-z. Epub 2021 Jun 16.</citation>
    <PMID>34136987</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <results_first_submitted>November 15, 2019</results_first_submitted>
  <results_first_submitted_qc>December 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2020</results_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immediate release tablet</keyword>
  <keyword>GSK2982772</keyword>
  <keyword>Modified release</keyword>
  <keyword>minitablet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study is available via the Clinical Study Data Request site</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20863</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03266172/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03266172/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open label, 3-part, single and repeat dose study conducted in healthy participants to assess modified release (MR) minitablets (MT) in a capsule and MR monolithic matrix (MM) formulations of GSK2982772 compared to immediate release (IR) tablet formulation of GSK2982772.</recruitment_details>
      <pre_assignment_details>In this study, total 45 participants were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MT-12hr Fasted/MT-8hr Fasted/IR Fasted/MT-12hr Fed (High Fat)</title>
          <description>Participants in Part A received a single dose of 120 mg GSK2982772 MR MT-12hour (hr) capsule (80% release at 12 hours) in fasted state in Period 1 followed by a single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state in Period 2. In Period 3, participants received a single oral dose of 120 milligram (mg) GSK2982772 (4x30 mg) IR tablet in fasted state followed by a single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal in Period 4. There was a washout period of 7 days between each treatment period. All doses were administered via the oral route with 240 milliliters (mL) of water.</description>
        </group>
        <group group_id="P2">
          <title>MT 120mg Fasted/MT 240mg Fasted/ MT 300mg Fed (Standard)</title>
          <description>Participants in Part B received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days in Period 1 followed by once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days in Period 2. In Period 3, participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days. There was washout period of 7 days between each treatment period. All doses were administered via oral route with 240 mL water.</description>
        </group>
        <group group_id="P3">
          <title>MM240 Fast/IR240 Fast/MM480 Fast/MM480 Fed/MM480 DF/MM240 DF</title>
          <description>Participants in Part C received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted (Fast) state in Period 1 followed by a single dose of 240 mg GSK2982772 IR tablet in fasted state in Period 2. In Period 3, participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. In Period 4, participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state followed by a single dose of 480 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before standard breakfast (delayed fed [DF]) in Period 5. In Period 6, participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before high-fat breakfast (DF). There was a washout period of 7 days between each treatment period. All doses were administered via oral route with 240 mL water</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A: Period 1(2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A: Washout Period (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A: Period 2 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Period 3 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">3 replacement participants were enrolled</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A: Period 4 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B: Period 1 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants from Part A did not enter Part B</participants>
                <participants group_id="P2" count="10">New participants were enrolled in Part B of study</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B: Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B: Period 2 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B: Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B: Period 3 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6">Two participants completed Washout Period but withdrew before the start of Period 3.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C: Period 1(2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0">Participants from Part B did not enter Part C</participants>
                <participants group_id="P3" count="15">New participants were enrolled in Part C of study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C Washout Period (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C Period 2(2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C Washout Period (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C Period 3(2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16">1 replacement participant enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C Washout Period (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C Period 4(2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C Washout Period (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C Period 5(2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part C Washout Period (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C Period 6(2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MT-12hr Fasted/MT-8hr Fasted/IR Fasted/MT-12hr Fed (High Fat)</title>
          <description>Participants in Part A received a single dose of 120 mg GSK2982772 MR MT-12hour (hr) capsule (80% release at 12 hours) in fasted state in Period 1 followed by a single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state in Period 2. In Period 3, participants received a single oral dose of 120 milligram (mg) GSK2982772 (4x30 mg) IR tablet in fasted state followed by a single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal in Period 4. There was a washout period of 7 days between each treatment period. All doses were administered via the oral route with 240 milliliters (mL) of water.</description>
        </group>
        <group group_id="B2">
          <title>MT 120mg Fasted/MT 240mg Fasted/ MT 300mg Fed (Standard)</title>
          <description>Participants in Part B received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days in Period 1 followed by once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days in Period 2. In Period 3, participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days. There was washout period of 7 days between each treatment period. All doses were administered via oral route with 240 mL water.</description>
        </group>
        <group group_id="B3">
          <title>MM240 Fast/IR240 Fast/MM480 Fast/MM480 Fed/MM480 DF/MM240 DF</title>
          <description>Participants in Part C received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted (Fast) state in Period 1 followed by a single dose of 240 mg GSK2982772 IR tablet in fasted state in Period 2. In Period 3, participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. In Period 4, participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state followed by a single dose of 480 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before standard breakfast (delayed fed [DF]) in Period 5. In Period 6, participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before high-fat breakfast (delayed fed). There was a washout period of 7 days between each treatment period. All doses were administered via oral route with 240 mL water</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="14.10"/>
                    <measurement group_id="B2" value="47.8" spread="13.43"/>
                    <measurement group_id="B3" value="45.3" spread="12.22"/>
                    <measurement group_id="B4" value="47.5" spread="13.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Participants in the 'Safety Population' for whom a Pharmacokinetic (PK) sample was obtained and analyzed were part of PK Population.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Participants in the 'Safety Population' for whom a Pharmacokinetic (PK) sample was obtained and analyzed were part of PK Population.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.305" spread="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf) of GSK2982772 in MT Formulation :Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf).</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf) of GSK2982772 in MT Formulation :Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf).</description>
          <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.852" spread="39.4"/>
                    <measurement group_id="O2" value="4.482" spread="47.4"/>
                    <measurement group_id="O3" value="5.314" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.258" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-t) of GSK2982772 in MT Formulation: Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A:MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) of GSK2982772 in MT Formulation: Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)</description>
          <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.805" spread="42.3"/>
                    <measurement group_id="O2" value="4.449" spread="49.4"/>
                    <measurement group_id="O3" value="4.720" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.256" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24) of GSK2982772 in MT Formulation: Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time frame were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) of GSK2982772 in MT Formulation: Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)</description>
          <population>PK Population. Only those participants with data available at specified time frame were analyzed</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.558" spread="43.6"/>
                    <measurement group_id="O2" value="4.255" spread="49.4"/>
                    <measurement group_id="O3" value="4.580" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.967" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-12) of GSK2982772 in MT Formulation: Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A:MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12) of GSK2982772 in MT Formulation: Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.106" spread="45.1"/>
                    <measurement group_id="O2" value="3.066" spread="47.7"/>
                    <measurement group_id="O3" value="3.573" spread="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax</description>
          <population>PK Population</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.375" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of GSK2982772 in MT Formulation: Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK2982772 in MT Formulation: Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.277" spread="58.8"/>
                    <measurement group_id="O2" value="0.439" spread="54.9"/>
                    <measurement group_id="O3" value="0.624" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for C12hour.</description>
        <time_frame>12 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
          <group group_id="O4">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for C12hour.</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.220" spread="52.6"/>
                    <measurement group_id="O2" value="0.209" spread="56.2"/>
                    <measurement group_id="O3" value="0.208" spread="53.1"/>
                    <measurement group_id="O4" value="0.045" spread="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for C24hour.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
          <group group_id="O4">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for C24hour.</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.058" spread="73.2"/>
                    <measurement group_id="O2" value="0.046" spread="69.5"/>
                    <measurement group_id="O3" value="0.030" spread="46.6"/>
                    <measurement group_id="O4" value="0.006" spread="108.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT (test) / Geometric mean of AUC (0-inf) of IR Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose (test)</time_frame>
        <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:120 mg MT-8hr Fasted and 120 mg IR Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses</description>
          </group>
          <group group_id="O2">
            <title>Part A:120 mg MT-12hr Fasted and 120 mg IR Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT (test) / Geometric mean of AUC (0-inf) of IR Formulation (reference) multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.77" lower_limit="67.91" upper_limit="77.98"/>
                    <measurement group_id="O2" value="60.53" lower_limit="56.15" upper_limit="65.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frelformulation Based on AUC (0-24) of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MT (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose (test)</time_frame>
        <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:120 mg MT-8hr Fasted and 120 mg IR Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses</description>
          </group>
          <group group_id="O2">
            <title>Part A:120 mg MT-12hr Fasted and 120 mg IR Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Frelformulation Based on AUC (0-24) of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MT (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.18" lower_limit="63.98" upper_limit="72.64"/>
                    <measurement group_id="O2" value="57.54" lower_limit="54.01" upper_limit="61.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frelformulation Based on Cmax of GSK2982772 in Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel was calculated as Geometric mean of Cmax of MT Formulation (test)/ Geometric mean of Cmax of IR Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose(test)</time_frame>
        <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:120 mg MT-8hr Fasted and 120 mg IR Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses</description>
          </group>
          <group group_id="O2">
            <title>Part A:120 mg MT-12hr Fasted and 120 mg IR Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state and received single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Frelformulation Based on Cmax of GSK2982772 in Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel was calculated as Geometric mean of Cmax of MT Formulation (test)/ Geometric mean of Cmax of IR Formulation (reference) multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.13" lower_limit="27.36" upper_limit="37.75"/>
                    <measurement group_id="O2" value="20.39" lower_limit="17.41" upper_limit="23.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.</description>
          <population>PK Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.485" spread="20.9265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.</description>
        <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.284" spread="0.2468"/>
                    <measurement group_id="O2" value="2.265" spread="0.9119"/>
                    <measurement group_id="O3" value="3.240" spread="1.2250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.</description>
        <time_frame>Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.</description>
          <population>PK Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.851" spread="221.7640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.</description>
        <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.119" spread="5.1507"/>
                    <measurement group_id="O2" value="10.790" spread="4.9019"/>
                    <measurement group_id="O3" value="22.915" spread="11.7978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of Tmax.</description>
        <time_frame>Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of Tmax.</description>
          <population>PK Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="0.67" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of GSK2982772 in MT Formulation: Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of Tmax.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GSK2982772 in MT Formulation: Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of Tmax.</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.000" lower_limit="2.08" upper_limit="18.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="4.00" upper_limit="10.00"/>
                    <measurement group_id="O3" value="6.000" lower_limit="4.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf)</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf)</description>
          <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.797" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf).</description>
        <time_frame>Pre-dose, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf).</description>
          <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.417" spread="23.4"/>
                    <measurement group_id="O2" value="22.493" spread="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-t).</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-t).</description>
          <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.621" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-t).</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-t).</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.676" spread="29.6"/>
                    <measurement group_id="O2" value="20.009" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.619" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.769" spread="30.9"/>
                    <measurement group_id="O2" value="18.177" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-12)</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-12)</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.500" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-12)</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-12)</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.096" spread="32.8"/>
                    <measurement group_id="O2" value="12.508" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of GSK2982772 for IR Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK2982772 for IR Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.938" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of GSK2982772 for MM Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK2982772 for MM Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.918" spread="34.2"/>
                    <measurement group_id="O2" value="2.010" spread="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C12 of GSK2982772 in Part C: Fasted State</title>
        <description>Blood samples was collected at indicated time point for analysis of C12</description>
        <time_frame>12 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>C12 of GSK2982772 in Part C: Fasted State</title>
          <description>Blood samples was collected at indicated time point for analysis of C12</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.197" spread="62.9"/>
                    <measurement group_id="O2" value="0.346" spread="41.7"/>
                    <measurement group_id="O3" value="0.671" spread="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C24 of GSK2982772 in Part C: Fasted State</title>
        <description>Blood samples was collected at indicated time point for analysis of C24</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>C24 of GSK2982772 in Part C: Fasted State</title>
          <description>Blood samples was collected at indicated time point for analysis of C24</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="54.9"/>
                    <measurement group_id="O2" value="0.162" spread="52.6"/>
                    <measurement group_id="O3" value="0.351" spread="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.</description>
          <population>PK Population.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.158" spread="7.9158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.</description>
          <population>PK Population.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.892" spread="1.2572"/>
                    <measurement group_id="O2" value="3.551" spread="2.2615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.</description>
        <time_frame>Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.</description>
          <population>PK Population.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.239" spread="76.3996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C: MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.</description>
          <population>PK Population.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.026" spread="2.1936"/>
                    <measurement group_id="O2" value="7.991" spread="10.6319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MM formulation (test) / Geometric mean of AUC (0-t) of IR Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose(test)</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C:MM-12h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants in received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state and a single dose of 240 mg GSK2982772 IR tablet in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MM formulation (test) / Geometric mean of AUC (0-t) of IR Formulation (reference) multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.18" lower_limit="61.91" upper_limit="70.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MM Fasted formulation (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose(test)</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part C:MM-12h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants in received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state and a single dose of 240 mg GSK2982772 IR tablet in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MM Fasted formulation (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.98" lower_limit="55.06" upper_limit="65.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after a high fat meal. Frel for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT Fed formulation (test) / Geometric mean of AUC (0-inf) of MT Fasted Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:120 mg MT-12hour Fed and 120 mg MT-12hour Fasted</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal and received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after a high fat meal. Frel for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT Fed formulation (test) / Geometric mean of AUC (0-inf) of MT Fasted Formulation (reference) multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.64" lower_limit="115.98" upper_limit="131.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A</title>
        <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772 after a high fat meal. Frel for Cmax was calculated as Geometric mean of Cmax of MT Fed formulation (test) / Geometric mean of Cmax of MT Fasted Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified timepoint were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part A:120 mg MT-12hour Fed and 120 mg MT-12hour Fasted</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal and received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A</title>
          <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772 after a high fat meal. Frel for Cmax was calculated as Geometric mean of Cmax of MT Fed formulation (test) / Geometric mean of Cmax of MT Fasted Formulation (reference) multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at specified timepoint were analyzed</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.07" lower_limit="201.78" upper_limit="251.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24) of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
        <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3</time_frame>
        <population>PK Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24) of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
          <population>PK Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Hours*microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=10, 9, 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.669" spread="26.5"/>
                    <measurement group_id="O2" value="8.807" spread="34.3"/>
                    <measurement group_id="O3" value="9.662" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, n=10, 10, 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.010" spread="32.0"/>
                    <measurement group_id="O2" value="9.867" spread="30.4"/>
                    <measurement group_id="O3" value="10.948" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
        <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
          <population>PK Population.</population>
          <units>Microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.417" spread="25.5"/>
                    <measurement group_id="O2" value="0.707" spread="44.7"/>
                    <measurement group_id="O3" value="0.888" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.398" spread="32.9"/>
                    <measurement group_id="O2" value="0.794" spread="35.7"/>
                    <measurement group_id="O3" value="1.080" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of GSK2982772 in Part B</title>
        <description>Blood samples were collected at indicated time points for analysis of Tmax</description>
        <time_frame>Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GSK2982772 in Part B</title>
          <description>Blood samples were collected at indicated time points for analysis of Tmax</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.058" lower_limit="4.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="4.067" lower_limit="4.00" upper_limit="12.00"/>
                    <measurement group_id="O3" value="4.000" lower_limit="4.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="2.00" upper_limit="16.0"/>
                    <measurement group_id="O2" value="5.025" lower_limit="4.00" upper_limit="20.00"/>
                    <measurement group_id="O3" value="4.000" lower_limit="4.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-24) of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
        <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C MM-12h 480mg Delayed Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O2">
            <title>Part C MM-12h 240mg Delayed Fed (High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
          <group group_id="O3">
            <title>Part C MM-12h 480mg Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-24) of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-24)</description>
          <population>PK Population</population>
          <units>Hours*microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.505" spread="29.5"/>
                    <measurement group_id="O2" value="8.734" spread="47.4"/>
                    <measurement group_id="O3" value="21.543" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
        <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C MM-12h 480mg Delayed Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O2">
            <title>Part C MM-12h 240mg Delayed Fed (High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
          <group group_id="O3">
            <title>Part C MM-12h 480mg Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of Cmax</description>
          <population>PK Population</population>
          <units>Microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.547" spread="40.8"/>
                    <measurement group_id="O2" value="1.064" spread="62.6"/>
                    <measurement group_id="O3" value="3.151" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C12 of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of C12</description>
        <time_frame>12 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C MM-12h 480mg Delayed Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O2">
            <title>Part C MM-12h 240mg Delayed Fed (High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
          <group group_id="O3">
            <title>Part C MM-12h 480mg Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>C12 of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of C12</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.706" spread="72.7"/>
                    <measurement group_id="O2" value="0.739" spread="37.1"/>
                    <measurement group_id="O3" value="0.317" spread="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-t) of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-t)</description>
        <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C MM-12h 480mg Delayed Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O2">
            <title>Part C MM-12h 240mg Delayed Fed (High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
          <group group_id="O3">
            <title>Part C MM-12h 480mg Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-t)</description>
          <population>PK Population</population>
          <units>Hours*microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.147" spread="28.0"/>
                    <measurement group_id="O2" value="9.202" spread="46.4"/>
                    <measurement group_id="O3" value="22.712" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-inf) of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf) after meal.</description>
        <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C MM-12h 480mg Delayed Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O2">
            <title>Part C MM-12h 240mg Delayed Fed (High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
          <group group_id="O3">
            <title>Part C MM-12h 480mg Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf) of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-inf) after meal.</description>
          <population>PK Population. Only participants with data available at the specified time points were analyzed.</population>
          <units>Hours*microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.941" spread="36.5"/>
                    <measurement group_id="O2" value="9.995" spread="62.4"/>
                    <measurement group_id="O3" value="24.367" spread="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-12) of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of AUC (0-12) after meal.</description>
        <time_frame>Pre-dose and at 2, 4, 6, 8, 10, and 12 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C MM-12h 480mg Delayed Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O2">
            <title>Part C MM-12h 240mg Delayed Fed (High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
          <group group_id="O3">
            <title>Part C MM-12h 480mg Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-12) of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of AUC (0-12) after meal.</description>
          <population>PK Population.</population>
          <units>Hours*microgram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.111" spread="45.0"/>
                    <measurement group_id="O2" value="10.241" spread="45.9"/>
                    <measurement group_id="O3" value="6.771" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after meal. Frel for Auc (0-t) was calculated as Geometric mean of AUC (0-t) of MM Fed formulation (fed) / Geometric mean of AUC (0-t) of MM Fasted Formulation (fasted) multiplied by 100.</description>
        <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C:480mg MM-12hour Delayed Fed and 480 mg MM-12hour Fasted</title>
            <description>Participants received single dose of 480 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before standard breakfast (delayed fed) and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses</description>
          </group>
          <group group_id="O2">
            <title>Part C:480mg MM-12hour Fed and 480 mg MM- 12hour Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses</description>
          </group>
          <group group_id="O3">
            <title>Part C:240mg MM-12hour Delayed Fed and 240mg MM-12hour Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before high-fat breakfast (delayed fed)) and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after meal. Frel for Auc (0-t) was calculated as Geometric mean of AUC (0-t) of MM Fed formulation (fed) / Geometric mean of AUC (0-t) of MM Fasted Formulation (fasted) multiplied by 100.</description>
          <population>PK Population</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.69" lower_limit="87.03" upper_limit="103.04"/>
                    <measurement group_id="O2" value="113.51" lower_limit="104.52" upper_limit="123.27"/>
                    <measurement group_id="O3" value="91.13" lower_limit="82.23" upper_limit="100.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frelformulation Based on Cmax of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 after meal. Frel for Cmax was calculated as Geometric mean of Cmax of MM Fed formulation (test) / Geometric mean of Cmax of MM Fasted Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C:480mg MM-12hour Delayed Fed and 480 mg MM-12hour Fasted</title>
            <description>Participants received single dose of 480 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before standard breakfast (delayed fed) and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses</description>
          </group>
          <group group_id="O2">
            <title>Part C:480mg MM-12hour Fed and 480 mg MM- 12hour Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses</description>
          </group>
          <group group_id="O3">
            <title>Part C:240mg MM-12hour Delayed Fed and 240mg MM-12hour Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours) before high-fat breakfast (delayed fed) and received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state. There was washout period of 7 days between doses</description>
          </group>
        </group_list>
        <measure>
          <title>Frelformulation Based on Cmax of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 after meal. Frel for Cmax was calculated as Geometric mean of Cmax of MM Fed formulation (test) / Geometric mean of Cmax of MM Fasted Formulation (reference) multiplied by 100.</description>
          <population>PK Population</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.56" lower_limit="64.25" upper_limit="91.22"/>
                    <measurement group_id="O2" value="156.77" lower_limit="132.06" upper_limit="186.09"/>
                    <measurement group_id="O3" value="113.81" lower_limit="94.00" upper_limit="137.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of GSK2982772 After Meal in Part C</title>
        <description>Blood samples were collected at indicated time points for analysis of Tmax of GSK2982772 after meal.</description>
        <time_frame>Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C MM-12h 480mg Delayed Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O2">
            <title>Part C MM-12h 240mg Delayed Fed (High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
          <group group_id="O3">
            <title>Part C MM-12h 480mg Fed (Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GSK2982772 After Meal in Part C</title>
          <description>Blood samples were collected at indicated time points for analysis of Tmax of GSK2982772 after meal.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.000" lower_limit="2.00" upper_limit="20.00"/>
                    <measurement group_id="O2" value="4.000" lower_limit="2.00" upper_limit="10.02"/>
                    <measurement group_id="O3" value="5.017" lower_limit="4.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A</title>
        <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. All participants who receive at least 1 dose of study treatment and were included in Safety Population. Participants will be analyzed according to the treatment they actually received.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A</title>
          <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. All participants who receive at least 1 dose of study treatment and were included in Safety Population. Participants will be analyzed according to the treatment they actually received.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With AE and SAE in Part B</title>
        <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AE and SAE in Part B</title>
          <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With AE and SAE in Part C</title>
        <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AE and SAE in Part C</title>
          <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
          <group group_id="O4">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, normal or no change16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A</title>
        <description>Blood samples were collected to analyze hematology parameters like platelet count, white blood cell (WBC) count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
          <group group_id="O4">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A</title>
          <description>Blood samples were collected to analyze hematology parameters like platelet count, white blood cell (WBC) count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Abnormal Urinalysis Dipstick Results: Part A</title>
        <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
          <group group_id="O4">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Abnormal Urinalysis Dipstick Results: Part A</title>
          <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B</title>
        <description>Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B</title>
          <description>Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Abnormal Urinalysis Dipstick Results: Part B</title>
        <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Abnormal Urinalysis Dipstick Results: Part B</title>
          <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C</title>
        <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C</title>
          <description>Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C</title>
        <description>Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C</title>
          <description>Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Abnormal Urinalysis Dipstick Results: Part C</title>
        <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Abnormal Urinalysis Dipstick Results: Part C</title>
          <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A</title>
        <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and Corrected QT (QTc) intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
          <group group_id="O4">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A</title>
          <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and Corrected QT (QTc) intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal, not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Abnormal ECG Findings: Part B</title>
        <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 22</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Abnormal ECG Findings: Part B</title>
          <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal, not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Abnormal ECG Findings: Part C</title>
        <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 43</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Abnormal ECG Findings: Part C</title>
          <description>Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal, not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal, clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure: Part A</title>
        <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure: Part A</title>
          <description>Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day 1, 2 hours, n=16,16, 13,16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="13.46"/>
                    <measurement group_id="O2" value="4.3" spread="10.70"/>
                    <measurement group_id="O3" value="-0.2" spread="16.53"/>
                    <measurement group_id="O4" value="-6.2" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day 1, 12 hours, n=15,16, 13,16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="14.05"/>
                    <measurement group_id="O2" value="-2.5" spread="14.27"/>
                    <measurement group_id="O3" value="-6.2" spread="12.34"/>
                    <measurement group_id="O4" value="-2.9" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day 2, 24 hours, n=16,16, 13,16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="13.86"/>
                    <measurement group_id="O2" value="-2.7" spread="9.76"/>
                    <measurement group_id="O3" value="-6.2" spread="11.22"/>
                    <measurement group_id="O4" value="-3.9" spread="14.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 2 hours, n=16,16, 13,16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="7.33"/>
                    <measurement group_id="O2" value="3.0" spread="8.12"/>
                    <measurement group_id="O3" value="-1.8" spread="7.81"/>
                    <measurement group_id="O4" value="-4.4" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day 1, 12 hours, n=16,16, 13,16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="10.01"/>
                    <measurement group_id="O2" value="-3.6" spread="9.87"/>
                    <measurement group_id="O3" value="-3.0" spread="9.27"/>
                    <measurement group_id="O4" value="-3.9" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day 2, 24 hours, n=16,16, 13,16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="8.51"/>
                    <measurement group_id="O2" value="0.7" spread="7.60"/>
                    <measurement group_id="O3" value="-1.7" spread="7.79"/>
                    <measurement group_id="O4" value="-1.1" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate: Part A</title>
        <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1 Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate: Part A</title>
          <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="5.11"/>
                    <measurement group_id="O2" value="-0.3" spread="4.88"/>
                    <measurement group_id="O3" value="-2.5" spread="7.62"/>
                    <measurement group_id="O4" value="3.9" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="6.06"/>
                    <measurement group_id="O2" value="5.2" spread="3.94"/>
                    <measurement group_id="O3" value="5.8" spread="5.57"/>
                    <measurement group_id="O4" value="7.5" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="9.41"/>
                    <measurement group_id="O2" value="-2.1" spread="6.31"/>
                    <measurement group_id="O3" value="0.6" spread="7.14"/>
                    <measurement group_id="O4" value="0.9" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Respiration Rate: Part A</title>
        <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiration Rate: Part A</title>
          <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value</description>
          <population>Safety Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.67"/>
                    <measurement group_id="O2" value="0.8" spread="1.65"/>
                    <measurement group_id="O3" value="0.0" spread="1.00"/>
                    <measurement group_id="O4" value="-1.5" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.71"/>
                    <measurement group_id="O2" value="-0.1" spread="1.82"/>
                    <measurement group_id="O3" value="-0.2" spread="1.21"/>
                    <measurement group_id="O4" value="-2.4" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.15"/>
                    <measurement group_id="O2" value="-0.1" spread="1.54"/>
                    <measurement group_id="O3" value="-1.5" spread="1.51"/>
                    <measurement group_id="O4" value="-1.4" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Temperature: Part A</title>
        <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 120mg Fasted</title>
            <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MT-12hour 120mg Fasted</title>
            <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part A: MT-8hour 120mg Fasted</title>
            <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MT-12hour 120mg Fed (High Fat)</title>
            <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature: Part A</title>
          <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.152"/>
                    <measurement group_id="O2" value="0.18" spread="0.180"/>
                    <measurement group_id="O3" value="0.05" spread="0.145"/>
                    <measurement group_id="O4" value="0.14" spread="0.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.139"/>
                    <measurement group_id="O2" value="-0.04" spread="0.145"/>
                    <measurement group_id="O3" value="0.13" spread="0.118"/>
                    <measurement group_id="O4" value="0.11" spread="0.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.182"/>
                    <measurement group_id="O2" value="0.07" spread="0.095"/>
                    <measurement group_id="O3" value="0.12" spread="0.114"/>
                    <measurement group_id="O4" value="0.12" spread="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure: Part B</title>
        <description>SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure: Part B</title>
          <description>SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="7.40"/>
                    <measurement group_id="O2" value="5.4" spread="7.37"/>
                    <measurement group_id="O3" value="1.2" spread="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="7.75"/>
                    <measurement group_id="O2" value="1.5" spread="8.86"/>
                    <measurement group_id="O3" value="1.0" spread="10.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day 2, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="5.26"/>
                    <measurement group_id="O2" value="3.5" spread="7.76"/>
                    <measurement group_id="O3" value="1.8" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day 3, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="9.35"/>
                    <measurement group_id="O2" value="1.1" spread="5.09"/>
                    <measurement group_id="O3" value="-0.7" spread="14.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day 3, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="8.37"/>
                    <measurement group_id="O2" value="5.5" spread="9.51"/>
                    <measurement group_id="O3" value="-3.3" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day 3, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="11.55"/>
                    <measurement group_id="O2" value="7.4" spread="14.17"/>
                    <measurement group_id="O3" value="3.8" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day 4, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="9.22"/>
                    <measurement group_id="O2" value="6.1" spread="5.04"/>
                    <measurement group_id="O3" value="6.0" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="7.31"/>
                    <measurement group_id="O2" value="2.1" spread="7.16"/>
                    <measurement group_id="O3" value="-4.0" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="5.50"/>
                    <measurement group_id="O2" value="-2.2" spread="4.59"/>
                    <measurement group_id="O3" value="-5.7" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day 2, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="4.55"/>
                    <measurement group_id="O2" value="2.0" spread="7.47"/>
                    <measurement group_id="O3" value="-2.7" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day 3, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="8.57"/>
                    <measurement group_id="O2" value="1.3" spread="6.65"/>
                    <measurement group_id="O3" value="1.3" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day 3, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="7.00"/>
                    <measurement group_id="O2" value="4.0" spread="5.31"/>
                    <measurement group_id="O3" value="-5.8" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day 3, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="7.78"/>
                    <measurement group_id="O2" value="-1.4" spread="5.72"/>
                    <measurement group_id="O3" value="-2.5" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day 4, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="5.56"/>
                    <measurement group_id="O2" value="4.6" spread="4.77"/>
                    <measurement group_id="O3" value="1.3" spread="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate: Part B</title>
        <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate: Part B</title>
          <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="5.50"/>
                    <measurement group_id="O2" value="-2.4" spread="5.38"/>
                    <measurement group_id="O3" value="7.3" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="4.00"/>
                    <measurement group_id="O2" value="8.8" spread="5.22"/>
                    <measurement group_id="O3" value="10.5" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="4.68"/>
                    <measurement group_id="O2" value="-0.8" spread="6.37"/>
                    <measurement group_id="O3" value="-1.8" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="4.74"/>
                    <measurement group_id="O2" value="-0.1" spread="5.88"/>
                    <measurement group_id="O3" value="1.5" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="5.37"/>
                    <measurement group_id="O2" value="-0.3" spread="5.36"/>
                    <measurement group_id="O3" value="4.0" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="4.58"/>
                    <measurement group_id="O2" value="10.6" spread="7.26"/>
                    <measurement group_id="O3" value="7.7" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="8.64"/>
                    <measurement group_id="O2" value="6.7" spread="10.01"/>
                    <measurement group_id="O3" value="0.3" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Respiration Rate: Part B</title>
        <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4 24 hours</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiration Rate: Part B</title>
          <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value</description>
          <population>Safety Population</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.27"/>
                    <measurement group_id="O2" value="-2.0" spread="2.00"/>
                    <measurement group_id="O3" value="-1.2" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.37"/>
                    <measurement group_id="O2" value="-2.5" spread="2.17"/>
                    <measurement group_id="O3" value="-1.5" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.49"/>
                    <measurement group_id="O2" value="-0.5" spread="2.07"/>
                    <measurement group_id="O3" value="-0.5" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.67"/>
                    <measurement group_id="O2" value="-0.5" spread="1.43"/>
                    <measurement group_id="O3" value="1.5" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.36"/>
                    <measurement group_id="O2" value="-1.0" spread="2.21"/>
                    <measurement group_id="O3" value="-0.7" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.02"/>
                    <measurement group_id="O2" value="-1.3" spread="2.16"/>
                    <measurement group_id="O3" value="-0.8" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.87"/>
                    <measurement group_id="O2" value="-1.0" spread="1.89"/>
                    <measurement group_id="O3" value="-0.3" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Temperature: Part B</title>
        <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MT-12 120mg Fasted</title>
            <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Part B :MT-12 240mg Fasted</title>
            <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Part B :MT-12hour 300mg Fed (Standard)</title>
            <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature: Part B</title>
          <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.298"/>
                    <measurement group_id="O2" value="-0.01" spread="0.233"/>
                    <measurement group_id="O3" value="0.00" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.181"/>
                    <measurement group_id="O2" value="0.08" spread="0.274"/>
                    <measurement group_id="O3" value="0.07" spread="0.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.184"/>
                    <measurement group_id="O2" value="-0.04" spread="0.158"/>
                    <measurement group_id="O3" value="0.12" spread="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.135"/>
                    <measurement group_id="O2" value="0.07" spread="0.271"/>
                    <measurement group_id="O3" value="0.23" spread="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.149"/>
                    <measurement group_id="O2" value="0.01" spread="0.260"/>
                    <measurement group_id="O3" value="-0.08" spread="0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.191"/>
                    <measurement group_id="O2" value="0.05" spread="0.242"/>
                    <measurement group_id="O3" value="0.05" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.171"/>
                    <measurement group_id="O2" value="0.11" spread="0.247"/>
                    <measurement group_id="O3" value="0.00" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure: Part C</title>
        <description>SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure: Part C</title>
          <description>SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="7.93"/>
                    <measurement group_id="O2" value="-0.6" spread="7.50"/>
                    <measurement group_id="O3" value="-0.6" spread="6.16"/>
                    <measurement group_id="O4" value="-4.9" spread="9.18"/>
                    <measurement group_id="O5" value="1.1" spread="16.02"/>
                    <measurement group_id="O6" value="-0.2" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="10.04"/>
                    <measurement group_id="O2" value="-2.6" spread="8.34"/>
                    <measurement group_id="O3" value="1.4" spread="12.06"/>
                    <measurement group_id="O4" value="0.1" spread="10.81"/>
                    <measurement group_id="O5" value="-7.3" spread="14.92"/>
                    <measurement group_id="O6" value="0.9" spread="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP,Day2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="8.02"/>
                    <measurement group_id="O2" value="-1.4" spread="6.71"/>
                    <measurement group_id="O3" value="-1.6" spread="8.39"/>
                    <measurement group_id="O4" value="-3.1" spread="8.50"/>
                    <measurement group_id="O5" value="2.6" spread="10.84"/>
                    <measurement group_id="O6" value="-7.5" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="7.41"/>
                    <measurement group_id="O2" value="-0.7" spread="6.43"/>
                    <measurement group_id="O3" value="2.0" spread="6.92"/>
                    <measurement group_id="O4" value="-4.3" spread="6.94"/>
                    <measurement group_id="O5" value="-0.6" spread="7.88"/>
                    <measurement group_id="O6" value="-1.9" spread="5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="7.23"/>
                    <measurement group_id="O2" value="-1.1" spread="6.36"/>
                    <measurement group_id="O3" value="-3.1" spread="6.53"/>
                    <measurement group_id="O4" value="-0.6" spread="8.02"/>
                    <measurement group_id="O5" value="-3.7" spread="9.61"/>
                    <measurement group_id="O6" value="0.0" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP,Day2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="7.21"/>
                    <measurement group_id="O2" value="1.0" spread="4.88"/>
                    <measurement group_id="O3" value="-0.5" spread="6.64"/>
                    <measurement group_id="O4" value="2.8" spread="6.37"/>
                    <measurement group_id="O5" value="0.7" spread="7.49"/>
                    <measurement group_id="O6" value="2.4" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate: Part C</title>
        <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate: Part C</title>
          <description>Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="6.94"/>
                    <measurement group_id="O2" value="-5.3" spread="6.19"/>
                    <measurement group_id="O3" value="0.0" spread="6.86"/>
                    <measurement group_id="O4" value="7.3" spread="6.56"/>
                    <measurement group_id="O5" value="8.2" spread="5.72"/>
                    <measurement group_id="O6" value="8.2" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="6.20"/>
                    <measurement group_id="O2" value="6.5" spread="9.73"/>
                    <measurement group_id="O3" value="11.2" spread="9.65"/>
                    <measurement group_id="O4" value="10.3" spread="6.94"/>
                    <measurement group_id="O5" value="9.3" spread="8.28"/>
                    <measurement group_id="O6" value="8.6" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="5.44"/>
                    <measurement group_id="O2" value="0.1" spread="6.41"/>
                    <measurement group_id="O3" value="-0.4" spread="3.77"/>
                    <measurement group_id="O4" value="0.4" spread="5.80"/>
                    <measurement group_id="O5" value="-0.9" spread="6.19"/>
                    <measurement group_id="O6" value="1.6" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Respiration Rate: Part C</title>
        <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiration Rate: Part C</title>
          <description>Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.37"/>
                    <measurement group_id="O2" value="0.6" spread="2.03"/>
                    <measurement group_id="O3" value="0.9" spread="2.90"/>
                    <measurement group_id="O4" value="-1.1" spread="2.95"/>
                    <measurement group_id="O5" value="1.8" spread="1.74"/>
                    <measurement group_id="O6" value="0.1" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.59"/>
                    <measurement group_id="O2" value="1.0" spread="2.85"/>
                    <measurement group_id="O3" value="0.6" spread="2.66"/>
                    <measurement group_id="O4" value="-1.1" spread="2.90"/>
                    <measurement group_id="O5" value="-0.3" spread="2.61"/>
                    <measurement group_id="O6" value="0.5" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.25"/>
                    <measurement group_id="O2" value="0.4" spread="3.07"/>
                    <measurement group_id="O3" value="0.6" spread="4.00"/>
                    <measurement group_id="O4" value="-2.2" spread="2.66"/>
                    <measurement group_id="O5" value="1.8" spread="2.31"/>
                    <measurement group_id="O6" value="0.4" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Temperature: Part C</title>
        <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: IR 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part C:MM-12h 240mg Fasted</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Part C:MM-12h 480mg Fasted</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part C:MM-12h 480mg Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part C:MM-12h 480mg Delayed Fed(Standard)</title>
            <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
          </group>
          <group group_id="O6">
            <title>Part C: MM-12h 240mg Delayed Fed(High Fat)</title>
            <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature: Part C</title>
          <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.245"/>
                    <measurement group_id="O2" value="-0.05" spread="0.192"/>
                    <measurement group_id="O3" value="-0.07" spread="0.215"/>
                    <measurement group_id="O4" value="0.23" spread="0.275"/>
                    <measurement group_id="O5" value="0.01" spread="0.228"/>
                    <measurement group_id="O6" value="0.10" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.197"/>
                    <measurement group_id="O2" value="-0.11" spread="0.229"/>
                    <measurement group_id="O3" value="-0.05" spread="0.271"/>
                    <measurement group_id="O4" value="0.12" spread="0.307"/>
                    <measurement group_id="O5" value="-0.14" spread="0.241"/>
                    <measurement group_id="O6" value="-0.10" spread="0.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.256"/>
                    <measurement group_id="O2" value="0.15" spread="0.261"/>
                    <measurement group_id="O3" value="-0.00" spread="0.239"/>
                    <measurement group_id="O4" value="0.10" spread="0.278"/>
                    <measurement group_id="O5" value="-0.09" spread="0.269"/>
                    <measurement group_id="O6" value="-0.01" spread="0.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious AEs and SAEs were collected up to Day 43 for Part A and Part C and up to Day 22 for Part B</time_frame>
      <desc>Non-serious AEs and SAEs were collected in Safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A:IR 120mg Fasted</title>
          <description>Participants received a single oral dose of 120 mg GSK2982772 (4x30 mg) IR tablet in fasted state</description>
        </group>
        <group group_id="E2">
          <title>Part A:MT-12hour 120mg Fasted</title>
          <description>Participants received a single dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state</description>
        </group>
        <group group_id="E3">
          <title>Part A:MT-8hour 120mg Fasted</title>
          <description>Participants received single dose of 120 mg GSK2982772 MR MT-8hour capsule (80% release at 8 hours) in fasted state</description>
        </group>
        <group group_id="E4">
          <title>Part A:MT-12hour 120mg Fed (High Fat)</title>
          <description>Participants received single oral dose of 120 mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) after high fat meal</description>
        </group>
        <group group_id="E5">
          <title>Part B:MT-12hour 120mg Fasted</title>
          <description>Participants received once daily dose of 120mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days.</description>
        </group>
        <group group_id="E6">
          <title>Part B:MT-12hour 240mg Fasted</title>
          <description>Participants received once daily dose of 240mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fasted state for 3 days</description>
        </group>
        <group group_id="E7">
          <title>Part B:MT-12hour 300mg Fed (Standard)</title>
          <description>Participants received once daily dose of 300mg GSK2982772 MR MT-12hour capsule (80% release at 12 hours) in fed state (standard meal) for 3 days</description>
        </group>
        <group group_id="E8">
          <title>Part C:IR 240mg Fasted</title>
          <description>Participants received a single dose of 240 mg GSK2982772 IR tablet in fasted state</description>
        </group>
        <group group_id="E9">
          <title>Part C:MM-12hour 240mg Fasted</title>
          <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hour tablet (80% release at 12 hours) in fasted state</description>
        </group>
        <group group_id="E10">
          <title>Part C:MM-12hour 480mg Fasted</title>
          <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fasted state</description>
        </group>
        <group group_id="E11">
          <title>Part C:MM-12hour 480mg Fed (Standard)</title>
          <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state</description>
        </group>
        <group group_id="E12">
          <title>Part C:MM-12hour 480mg Delayed Fed (Standard)</title>
          <description>Participants received a single dose of 480 mg GSK2982772 MR MM-12 hour tablet (80% release at 12 hours) in fed state. Participants had received a dose before standard breakfast (delayed fed).</description>
        </group>
        <group group_id="E13">
          <title>Part C:MM-12hour 240mg Delayed Fed (High Fat)</title>
          <description>Participants received a single dose of 240 mg GSK2982772 MR MM-12hours (80% release at 12 hours). Participants had received a dose before high-fat breakfast (delayed fed).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injury associated with device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Reponse Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03266172
org study id: 205017
nct id: NCT03266172
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
GSK2982772 is a first-in-class, highly selective, receptor-interacting protein-1 (RIP1)
      kinase inhibitor being developed for the treatment of inflammatory bowel disease, plaque
      psoriasis (PsO), rheumatoid arthritis (RA) and other disease conditions. PK data from the
      first time in human (FTIH) study for GSK2982772 showed that the half life of GSK2982772 was
      short (approximately 2 to 3 hours). A once daily (QD) formulation would be more convenient
      from a subject perspective and could offer the advantage of providing a flatter GSK2982772
      concentration time profile. Following completion of Parts A and B, it was determined that the
      slowest minitab formulation provided a PK profile suitable for QD dosing but this formulation
      was susceptible to a food effect. This study will evaluate the pharmacokinetics of GSK2982772
      following administration of different minitab MR formulations in a capsule relative to an IR
      reference tablet formulation, the pharmacokinetics of selected MR formulation in capsule
      following repeat doses for 3 days and to compare the pharmacokinetics of GSK2982772 following
      administration of MR tablet formulations in the fed and fasted state relative to an IR tablet
      formulation. The study is divided into three parts: Part A will be a non-randomized 6
      periods, sequential, 6-way fixed sequence design in which up to 4 MR minitab formulations in
      a capsule will be evaluated. Periods 1, 2, and 3 will evaluate a slow MR release duration
      (nominally 24 hours), a fast MR release duration (nominally 10 hours), and IR tablet
      respectively. Periods 4, 5 and 6 will have flexible dose regimen and it will depend on the
      outcomes of Period 1 to 3. Subjects will be admitted to the clinic the previous day before
      dosing. Each in-patient period will consist of 3 days and 2 nights followed by a minimum
      washout period of 7 days between doses, for both Part A and C. In Part A and C, 16 healthy
      subjects will be enrolled such that at least 12 evaluable subjects complete the study. Part B
      will be an open-label, repeat dose study in which the selected MR minitab formulation in
      capsule will be evaluated. Each in-patient period will consist of 5 days and 4 nights. There
      will be a minimum of 7 days washout period between the last morning dose of one period and
      the first dose of the next period. In Part B, 10 healthy subjects will be enrolled such that
      at least 6 evaluable subjects complete the study. Part C of the study will be a
      non-randomised 6 period, sequential, fixed sequence crossover design in which MR tablet
      formulations will be evaluated. Periods 1 and 2 will evaluate single dose administration of a
      240 milligram (mg) MR tablet and the 240 mg IR tablet (reference), respectively. Periods 3,
      4, 5 and 6 will be flexible and the dosing regimen will be dependent on the outcome of
      Periods 1 and 2.
allocation: Non-Randomized
intervention model: Sequential Assignment
intervention model description: Part A of the study will be a non-randomized 6 period, sequential, 6-way fixed sequence design. Part B of the study will be a repeat dose study. Part C of the study will be a non-randomized 6 period, sequential, fixed sequence crossover design.
primary purpose: Treatment
masking: None (Open Label)
measure: Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Participants in the 'Safety Population' for whom a Pharmacokinetic (PK) sample was obtained and analyzed were part of PK Population.
measure: AUC(0-inf) of GSK2982772 in MT Formulation :Part A
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf).
measure: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)
measure: AUC(0-t) of GSK2982772 in MT Formulation: Part A
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)
measure: Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)
measure: AUC(0-24) of GSK2982772 in MT Formulation: Part A
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)
measure: Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)
measure: AUC(0-12) of GSK2982772 in MT Formulation: Part A
time frame: Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)
measure: Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for Cmax
measure: Cmax of GSK2982772 in MT Formulation: Part A
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for Cmax
measure: Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A
time frame: 12 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for C12hour.
measure: Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A
time frame: 24 hours post-dose
description: Blood samples were collected from participants at indicated time points and analyzed for C24hour.
measure: Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose (test)
description: Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT (test) / Geometric mean of AUC (0-inf) of IR Formulation (reference) multiplied by 100.
measure: Frelformulation Based on AUC (0-24) of GSK2982772 in Part A
time frame: Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose (test)
description: Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MT (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.
measure: Frelformulation Based on Cmax of GSK2982772 in Part A
time frame: Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose(test)
description: Blood samples were collected at indicated time points for analysis of Frelformulation. Frel was calculated as Geometric mean of Cmax of MT Formulation (test)/ Geometric mean of Cmax of IR Formulation (reference) multiplied by 100.
measure: Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.
measure: Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A
time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.
measure: Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A
time frame: Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.
measure: Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A
time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.
measure: Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A
time frame: Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of Tmax.
measure: Tmax of GSK2982772 in MT Formulation: Part A
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of Tmax.
measure: AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-inf)
measure: AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State
time frame: Pre-dose, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-inf).
measure: AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-t).
measure: AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-t).
measure: AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-24)
measure: AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-24)
measure: AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-12)
measure: AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State
time frame: Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-12)
measure: Cmax of GSK2982772 for IR Formulation in Part C: Fasted State
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of Cmax
measure: Cmax of GSK2982772 for MM Formulation in Part C: Fasted State
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of Cmax
measure: C12 of GSK2982772 in Part C: Fasted State
time frame: 12 hours post-dose
description: Blood samples was collected at indicated time point for analysis of C12
measure: C24 of GSK2982772 in Part C: Fasted State
time frame: 24 hours post-dose
description: Blood samples was collected at indicated time point for analysis of C24
measure: Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.
measure: Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.
measure: Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State
time frame: Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.
measure: Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State
time frame: Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.
measure: Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose(test)
description: Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MM formulation (test) / Geometric mean of AUC (0-t) of IR Formulation (reference) multiplied by 100.
measure: Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State
time frame: Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose(test)
description: Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MM Fasted formulation (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.
measure: Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A
time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after a high fat meal. Frel for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT Fed formulation (test) / Geometric mean of AUC (0-inf) of MT Fasted Formulation (reference) multiplied by 100.
measure: Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A
time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772 after a high fat meal. Frel for Cmax was calculated as Geometric mean of Cmax of MT Fed formulation (test) / Geometric mean of Cmax of MT Fasted Formulation (reference) multiplied by 100.
measure: AUC(0-24) of GSK2982772 in Part B
time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3
description: Blood samples were collected at indicated time points for analysis of AUC (0-24)
measure: Cmax of GSK2982772 in Part B
time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3
description: Blood samples were collected at indicated time points for analysis of Cmax
measure: Tmax of GSK2982772 in Part B
time frame: Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3
description: Blood samples were collected at indicated time points for analysis of Tmax
measure: AUC (0-24) of GSK2982772 After Meal in Part C
time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-24)
measure: Cmax of GSK2982772 After Meal in Part C
time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours
description: Blood samples were collected at indicated time points for analysis of Cmax
measure: C12 of GSK2982772 After Meal in Part C
time frame: 12 hours post-dose
description: Blood samples were collected at indicated time points for analysis of C12
measure: AUC(0-t) of GSK2982772 After Meal in Part C
time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-t)
measure: AUC(0-inf) of GSK2982772 After Meal in Part C
time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-inf) after meal.
measure: AUC(0-12) of GSK2982772 After Meal in Part C
time frame: Pre-dose and at 2, 4, 6, 8, 10, and 12 hours post-dose
description: Blood samples were collected at indicated time points for analysis of AUC (0-12) after meal.
measure: Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C
time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after meal. Frel for Auc (0-t) was calculated as Geometric mean of AUC (0-t) of MM Fed formulation (fed) / Geometric mean of AUC (0-t) of MM Fasted Formulation (fasted) multiplied by 100.
measure: Frelformulation Based on Cmax of GSK2982772 After Meal in Part C
time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 after meal. Frel for Cmax was calculated as Geometric mean of Cmax of MM Fed formulation (test) / Geometric mean of Cmax of MM Fasted Formulation (reference) multiplied by 100.
measure: Tmax of GSK2982772 After Meal in Part C
time frame: Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose
description: Blood samples were collected at indicated time points for analysis of Tmax of GSK2982772 after meal.
measure: Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A
time frame: Up to Day 43
description: An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. All participants who receive at least 1 dose of study treatment and were included in Safety Population. Participants will be analyzed according to the treatment they actually received.
measure: Number of Participants With AE and SAE in Part B
time frame: Up to Day 22
description: An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.
measure: Number of Participants With AE and SAE in Part C
time frame: Up to Day 43
description: An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.
measure: Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A
time frame: Up to Day 43
description: Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
measure: Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A
time frame: Up to Day 43
description: Blood samples were collected to analyze hematology parameters like platelet count, white blood cell (WBC) count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
measure: Number of Participants Abnormal Urinalysis Dipstick Results: Part A
time frame: Up to Day 43
description: Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.
measure: Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B
time frame: Up to Day 22
description: Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
measure: Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B
time frame: Up to Day 22
description: Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
measure: Number of Participants Abnormal Urinalysis Dipstick Results: Part B
time frame: Up to Day 22
description: Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.
measure: Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C
time frame: Up to Day 43
description: Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
measure: Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C
time frame: Up to Day 43
description: Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants are counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.
measure: Number of Participants Abnormal Urinalysis Dipstick Results: Part C
time frame: Up to Day 43
description: Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.
measure: Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A
time frame: Up to Day 43
description: Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and Corrected QT (QTc) intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.
measure: Number of Participants Abnormal ECG Findings: Part B
time frame: Up to Day 22
description: Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.
measure: Number of Participants Abnormal ECG Findings: Part C
time frame: Up to Day 43
description: Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.
measure: Change From Baseline in Blood Pressure: Part A
time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours
description: Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Heart Rate: Part A
time frame: Baseline (Day 1 Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours
description: Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Respiration Rate: Part A
time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours
description: Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value
measure: Change From Baseline in Body Temperature: Part A
time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours
description: Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Blood Pressure: Part B
time frame: Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours
description: SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Heart Rate: Part B
time frame: Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours
description: Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Respiration Rate: Part B
time frame: Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4 24 hours
description: Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value
measure: Change From Baseline in Body Temperature: Part B
time frame: Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours
description: Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Blood Pressure: Part C
time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours
description: SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Heart Rate: Part C
time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours
description: Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Respiration Rate: Part C
time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours
description: Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
measure: Change From Baseline in Body Temperature: Part C
time frame: Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours
description: Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.
arm group label: Subjects in Part A
arm group type: Experimental
description: Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)
arm group label: Subjects in Part B
arm group type: Experimental
description: Subjects in Part B will receive GSK2982772 MR
arm group label: Subjects in Part C
arm group type: Experimental
description: Subjects in Part C will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2)
intervention type: Drug
intervention name: GSK2982772 Modified Release
description: GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
arm group label: Subjects in Part A
arm group label: Subjects in Part B
arm group label: Subjects in Part C
intervention type: Drug
intervention name: GSK2982772 Immediate Release
description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
arm group label: Subjects in Part A
arm group label: Subjects in Part C
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: United Kingdom
citation: Tompson DJ, Whitaker M, Pan R, Johnson G, Fuller T, McKenzie L, Zann V, Powell M, Abbott-Banner K, Hawkins S. Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772. Pharm Res. 2021 Jul;38(7):1235-1245. doi: 10.1007/s11095-021-03059-z. Epub 2021 Jun 16.
PMID: 34136987
responsible party type: Sponsor
mesh term: Autoimmune Diseases
sharing ipd: Yes
ipd description: IPD for this study is available via the Clinical Study Data Request site
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd info type: Clinical Study Report (CSR)
ipd time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
ipd access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
ipd url: https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20863
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 